Abstract
Original language | English |
---|---|
Pages (from-to) | 2080-2100 |
Number of pages | 21 |
Journal | Chest |
Volume | 160 |
Issue number | 6 |
DOIs | |
Publication status | Published - 1 Dec 2021 |
Keywords
- KEY WORDS
- COPD
- physical activity
- systematic review
- OBSTRUCTIVE PULMONARY-DISEASE
- LUNG-VOLUME REDUCTION
- ALL-CAUSE MORTALITY
- WALKING PROGRAM
- SELF-EFFICACY
- REHABILITATION
- PEDOMETER
- BEHAVIOR
- TELEREHABILITATION
- INTERVENTION
Access to Document
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Chest, Vol. 160, No. 6, 01.12.2021, p. 2080-2100.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Objectively Measured Physical Activity as a COPD Clinical Trial Outcome
AU - Burtin, C.
AU - Mohan, D.
AU - Troosters, T.
AU - Watz, H.
AU - Hopkinson, N.S.
AU - Garcia-Aymerich, J.
AU - Moy, M.L.
AU - Vogiatzis, I.
AU - Rossiter, H.B.
AU - Singh, S.
AU - Merrill, D.D.
AU - Hamilton, A.
AU - Rennard, S.I.
AU - Fageras, M.
AU - Petruzzelli, S.
AU - Tal-Singer, R.
AU - Tomaszewski, E.
AU - Corriol-Rohou, S.
AU - Rochester, C.L.
AU - Sciurba, F.C.
AU - Casaburi, R.
AU - Man, W.D.C.
AU - Van Lummel, R.C.
AU - Cooper, C.B.
AU - Demeyer, H.
AU - Spruit, M.A.
AU - Vaes, A.
AU - CBQC Task Force on Physical Activity
N1 - Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: D. M. is a former employee and shareholder of GSK at the time the work was conducted; she is a current employee and shareholder of Genentech/Roche. J. G.-A. reports other from AstraZeneca, other from Esteve, other from Chiesi, other from Menarini, outside the submitted work. A. H. is an employee of Boehringer Ingelheim (Canada) Ltd. S. I. R. was an employee of AstraZeneca during the preparation of the manuscript and has since consulted with GSK and BerGenBio. M. F. is a full-time employee of AstraZeneca. S. P. is an employee of Chiesi Farmaceutici SpA. R. T.-S. is a former employee and current shareholder of GSK and reports consulting fees from ImmunoMet. E. T. is a full-time employee of AstraZeneca . S. C.-R. is an employee of AstraZeneca . C. L. R. is participating in a clinical trial for COPD treatment funded by AstraZeneca and has participated previously in clinical COPD trials funded by GSK Pharmaceuticals, Inc and Boehringer Ingelheim Pharmaceuticals; she has also participated on COPS scientific advisory boards of GSK Pharmaceuticals, Inc and Boehringer Ingelheim in the past; and served as the chair of the American Thoracic Society on Pulmonary Rehabilitation from 2015 to 2017. W. D.-C. M. reports personal fees from Jazz Pharmaceuticals , Mundipharma, and Novartis ; grants from Pfizer , the National Institute for Health Research , and the British Lung Foundation , outside the submitted work; and nonfinancial support from GSK. R. C. V. L. is owner and chairman of McRoberts. C. B. C. reports grants from the National Institutes of Health / National Heart, Lung, and Blood Institute and the Foundation for the National Institutes of Health during the conduct of the study; he reports personal fees from PulmonX, NUVAIRA, and MGC Diagnostics outside the submitted work; and between April 2016 and September 2019 he was employed part-time by GSK as a Global Medical Expert. None declared (C. B, T. T., H. W., N. S. H., M. L. M., I. V., H. B. R., S. S., D. D. M., F. C. S., R. C., H. D., M. A. S., A. V.). Funding Information: FUNDING/SUPPORT: Funding for the COPD Biomarkers Qualification Consortium Working Group was provided by AstraZeneca, Boehringer Ingelheim, GSK, and Chiesi.Author contributions: C. B. acts as the guarantor of the content of the manuscript. C. B. and A. V. took part in the conception of the work, performed the systematic literature search, analyzed and interpreted the data, and drafted the report. D. M. T. T. D. D. M. and M. A. S. took part in the conception of the work, provided regular feedback during the review process, and critically revised the draft. H. W. N. S. H. J. G.-A. M. L. M. I. V. H. B. R. S. S. A. H. S. I. R. M. F. S. P. R. T.-S. E. T. S. C.-R. C. L. R. F. C. S. R. C. W. D.-C. M. R. C. V. L. C. B. C. and H. D. took part in the conception of the work and critically revised the draft. All authors approved the final version of the work and agree to be accountable for all aspects of the work they have performed. Financial/nonfinancial disclosures: The authors have reported to CHEST the following: D. M. is a former employee and shareholder of GSK at the time the work was conducted; she is a current employee and shareholder of Genentech/Roche. J. G.-A. reports other from AstraZeneca, other from Esteve, other from Chiesi, other from Menarini, outside the submitted work. A. H. is an employee of Boehringer Ingelheim (Canada) Ltd. S. I. R. was an employee of AstraZeneca during the preparation of the manuscript and has since consulted with GSK and BerGenBio. M. F. is a full-time employee of AstraZeneca. S. P. is an employee of Chiesi Farmaceutici SpA. R. T.-S. is a former employee and current shareholder of GSK and reports consulting fees from ImmunoMet. E. T. is a full-time employee of AstraZeneca. S. C.-R. is an employee of AstraZeneca. C. L. R. is participating in a clinical trial for COPD treatment funded by AstraZeneca and has participated previously in clinical COPD trials funded by GSK Pharmaceuticals, Inc and Boehringer Ingelheim Pharmaceuticals; she has also participated on COPS scientific advisory boards of GSK Pharmaceuticals, Inc and Boehringer Ingelheim in the past; and served as the chair of the American Thoracic Society on Pulmonary Rehabilitation from 2015 to 2017. W. D.-C. M. reports personal fees from Jazz Pharmaceuticals, Mundipharma, and Novartis; grants from Pfizer, the National Institute for Health Research, and the British Lung Foundation, outside the submitted work; and nonfinancial support from GSK. R. C. V. L. is owner and chairman of McRoberts. C. B. C. reports grants from the National Institutes of Health/National Heart, Lung, and Blood Institute and the Foundation for the National Institutes of Health during the conduct of the study; he reports personal fees from PulmonX, NUVAIRA, and MGC Diagnostics outside the submitted work; and between April 2016 and September 2019 he was employed part-time by GSK as a Global Medical Expert. None declared (C. B, T. T. H. W. N. S. H. M. L. M. I. V. H. B. R. S. S. D. D. M. F. C. S. R. C. H. D. M. A. S. A. V.). Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript. Additional information: The e-Appendix, e-Figure, and e-Table can be found in the Supplemental Materials section of the online article. Publisher Copyright: © 2021 American College of Chest Physicians
PY - 2021/12/1
Y1 - 2021/12/1
N2 - BACKGROUND: Reduced physical activity is common in COPD and is associated with poor outcomes. Physical activity is therefore a worthy target for intervention in clinical trials; however, trials evaluating physical activity have used heterogeneous methods. RESEARCH QUESTION: What is the available evidence on the efficacy and/or effectiveness of various interventions to enhance objectively measured physical activity in patients with COPD, taking into account the minimal preferred methodologic quality of physical activity assessment? STUDY DESIGN AND METHODS: In this narrative review, the COPD Biomarker Qualification Consortium (CBQC) task force searched three scientific databases for articles that reported the effect of an intervention on objectively measured physical activity in COPD. Based on scientific literature and expert consensus, only studies with >_ 7 measurement days and >_ 4 valid days of >_ 8 h of monitoring were included in the primary analysis. RESULTS: Thirty-seven of 110 (34%) identified studies fulfilled the criteria, investigating the efficacy and/or effectiveness of physical activity behavior change programs (n = 7), mobile or electronic-health interventions (n = 9), rehabilitative exercise (n = 9), bronchodilation (n = 6), lung volume reduction procedures (n = 3), and other interventions (n = 3). Results are generally variable, reflecting the large differences in study characteristics and outcomes. Few studies show an increase beyond the proposed minimal important change of 600 to 1100 daily steps, indicating that enhancing physical activity levels is a challenge. INTERPRETATION: Only one-third of clinical trials measuring objective physical activity in people with COPD fulfilled the preset criteria regarding physical activity assessment. Studies showed variable effects on physical activity even when investigating similar interventions.
AB - BACKGROUND: Reduced physical activity is common in COPD and is associated with poor outcomes. Physical activity is therefore a worthy target for intervention in clinical trials; however, trials evaluating physical activity have used heterogeneous methods. RESEARCH QUESTION: What is the available evidence on the efficacy and/or effectiveness of various interventions to enhance objectively measured physical activity in patients with COPD, taking into account the minimal preferred methodologic quality of physical activity assessment? STUDY DESIGN AND METHODS: In this narrative review, the COPD Biomarker Qualification Consortium (CBQC) task force searched three scientific databases for articles that reported the effect of an intervention on objectively measured physical activity in COPD. Based on scientific literature and expert consensus, only studies with >_ 7 measurement days and >_ 4 valid days of >_ 8 h of monitoring were included in the primary analysis. RESULTS: Thirty-seven of 110 (34%) identified studies fulfilled the criteria, investigating the efficacy and/or effectiveness of physical activity behavior change programs (n = 7), mobile or electronic-health interventions (n = 9), rehabilitative exercise (n = 9), bronchodilation (n = 6), lung volume reduction procedures (n = 3), and other interventions (n = 3). Results are generally variable, reflecting the large differences in study characteristics and outcomes. Few studies show an increase beyond the proposed minimal important change of 600 to 1100 daily steps, indicating that enhancing physical activity levels is a challenge. INTERPRETATION: Only one-third of clinical trials measuring objective physical activity in people with COPD fulfilled the preset criteria regarding physical activity assessment. Studies showed variable effects on physical activity even when investigating similar interventions.
KW - KEY WORDS
KW - COPD
KW - physical activity
KW - systematic review
KW - OBSTRUCTIVE PULMONARY-DISEASE
KW - LUNG-VOLUME REDUCTION
KW - ALL-CAUSE MORTALITY
KW - WALKING PROGRAM
KW - SELF-EFFICACY
KW - REHABILITATION
KW - PEDOMETER
KW - BEHAVIOR
KW - TELEREHABILITATION
KW - INTERVENTION
U2 - 10.1016/j.chest.2021.06.044
DO - 10.1016/j.chest.2021.06.044
M3 - Article
C2 - 34217679
SN - 0012-3692
VL - 160
SP - 2080
EP - 2100
JO - Chest
JF - Chest
IS - 6
ER -